ZOM - Zomedica Pharmaceuticals Corp.

NYSE American - NYSE American Delayed Price. Currency in USD
0.3610
-0.0090 (-2.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.3700
Open0.3434
Bid0.0000 x 1200
Ask0.3740 x 800
Day's Range0.3350 - 0.3610
52 Week Range0.2800 - 2.9800
Volume101,741
Avg. Volume170,591
Market Cap38.249M
Beta (3Y Monthly)-0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.1800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire29 days ago

    Zomedica Pharmaceuticals Corp. Announces Pricing of $3 Million Underwritten Public Offering of Common Shares

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 6,521,740 common shares, at a price to the public of $0.46 per share.  The Company expects to receive gross proceeds of approximately $3 million from the offering.  The offering is expected to close on or about March 28, 2019, subject to customary closing conditions. H.C. Wainwright & Co. is acting as sole book-running manager for the offering.

  • GlobeNewswirelast month

    Zomedica Pharmaceuticals Corp. Announces Proposed Public Offering of Common Shares

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced it has commenced an underwritten public offering of its common shares. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of common shares sold in connection with the offering. The Company intends to use the net proceeds from the offering for the continued development of its diagnostic platform and therapeutic candidates, including making milestone payments, as they come due, under the Company’s existing license and collaboration agreements, and other general corporate and working capital purposes.

  • GlobeNewswire2 months ago

    Zomedica Initiates ZM-006 Pilot Efficacy Study and Provides Corporate Updates

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, initiated enrollment in its pilot efficacy study at the University of Georgia College of Veterinary Medicine to evaluate ZM-006, a transdermal methimazole formulation for the treatment of chronic hyperthyroidism in cats. The ZM-006 pilot efficacy study is being conducted to evaluate Zomedica’s transdermal methimazole formulation and, assuming positive study results, provide data for a future FDA Center for Veterinary Medicine (FDA-CVM) approved pivotal trial.

  • GlobeNewswire2 months ago

    Zomedica Pharmaceuticals Corp. Announces Year End 2018 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the year ended December 31, 2018.

  • GlobeNewswire3 months ago

    Zomedica Appoints Dr. Bonnie Bragdon as Vice President of Veterinary Affairs

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced the appointment of Bonnie Bragdon, DVM, MS, as Vice President of Veterinary Affairs. In this new company position, she will lead the veterinary medical strategy as it relates to industry trends, strategic partnerships, marketing, education and training to support Zomedica’s commercial product strategy, reporting to Chief Commercial Officer Bruk Herbst. “I am pleased to welcome Dr. Bragdon to the Zomedica Team.

  • GlobeNewswire3 months ago

    Zomedica Announces $4.28 Million Private Placement Closing and Corporate Update

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today announced the completion of its previously announced private placement offering, pursuant to which it has issued an aggregate of 2,815,789 common shares at a price of $1.52 (C$2.00) per share, for aggregate gross proceeds of $4,280,000 (approximately C$5,649,600), in the United States to accredited investors only pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D thereunder. Zomedica intends to use the net proceeds of the offering to fund its cash expenditure obligations under the Company’s exclusive development and supply agreement with Qorvo Biotechnologies, LLC (Qorvo), a wholly-owned subsidiary of Qorvo, Inc. (QRVO).

  • GlobeNewswire4 months ago

    Zomedica Provides Update on Pipeline Development and Announces At-The-Market Offering Program

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today provided an update on its pipeline development and announced the entering into of an at-the-market equity offering sales agreement with Cantor Fitzgerald & Co. “2018 was an industrious year in the development and expansion of our diagnostic pipeline alongside the continued development of our therapeutic candidates,” stated Gerald Solensky, Jr., Chairman and Chief Executive Officer at Zomedica. Joint development work initially targets five assay candidates to detect certain thyroid and adrenal disorders in dogs and cats, which currently require reference lab immunoassay testing for reliable diagnostic results.

  • PR Newswire4 months ago

    IncellDx and Zomedica Sign Diagnostic CTC Assay Development Agreement for Canine Cancer

    SAN CARLOS, Calif. , Dec. 19, 2018 /PRNewswire/ -- IncellDx, a leading single cell cancer diagnostics company, today announced it has entered into an assay development agreement with Zomedica (NYSE American: ...

  • Qorvo, Zomedica Tie-Up to Enhance Vet Health with BAW Sensors
    Zacks5 months ago

    Qorvo, Zomedica Tie-Up to Enhance Vet Health with BAW Sensors

    Qorvo's (QRVO) subsidiary, Qorvo Biotechnologies, inked a deal with Zomedica to improve the veterinary health domain with BAW-based filter technology.

  • GlobeNewswire5 months ago

    Zomedica Signs Exclusive Agreement with Qorvo Biotechnologies for Global Veterinary Rights to Diagnostic Point-of-Care Platform

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced it has entered into a development and supply agreement with Qorvo Biotechnologies, LLC (Qorvo), a wholly-owned subsidiary of Qorvo, Inc. (QRVO) focused on bringing its piezo-electric Bulk Acoustic Wave (BAW) sensor to the veterinary health sector. Under the terms of this agreement, Zomedica has exclusive, global rights to develop and market Qorvo’s investigational point-of-care diagnostic platform for veterinary use.

  • GlobeNewswire5 months ago

    Zomedica Announces $10 Million Private Offering of Common Shares

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today announced it is conducting a private offering of 6,578,947 common shares at a price of U.S.$1.52 (C$2.00) per share, for aggregate gross proceeds of up to U.S.$10,000,000 (approximately C$13,200,000), in the United States to accredited investors only pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D thereunder. Zomedica intends to use the net proceeds of the offering to fund its cash expenditure obligations under the Company’s exclusive development and supply agreement with Qorvo Biotechnologies, LLC (Qorvo), a wholly-owned subsidiary of Qorvo, Inc. (QRVO), announced via press release today.

  • GlobeNewswire5 months ago

    Analysis: Positioning to Benefit within Dominion Energy Midstream Partners, LP, Blue Capital Reinsurance, CRH Medical, Friedman Industries, CM Finance, and Zomedica Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    Zomedica Pharmaceuticals Corp. Announces Third Quarter 2018 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the third quarter ended September 30, 2018. Zomedica recorded net loss and comprehensive loss for the three and nine months ended September 30, 2018 of $1,910,278 or $0.02 per share and $8,226,005 or $0.09 per share, compared to a loss of $2,080,682 or $0.02 per share and $5,501,788 or $0.06 per share for the three and nine months ended September 30, 2017. Zomedica, which is in the development stage, recorded no revenues in the three and nine months ended September 30, 2018.

  • GlobeNewswire5 months ago

    Zomedica Pharmaceuticals Corp. to Present at Jefferies 2018 London Healthcare Conference and LD Micro Main Event XI

    ANN ARBOR, Mich., Nov. 12, 2018 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it.

  • ACCESSWIRE6 months ago

    SeeThruEquity Issues Update on Zomedica Pharmaceuticals Corp.

    NEW YORK, NY / ACCESSWIRE / October 16, 2018 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has issued an update note on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (ZOM). The report is available here: ZOM Update Note. Based in Ann Arbor, MI, Zomedica Pharmaceuticals Corp. (NYSE American: ZOM, TSXV: ZOM, "Zomedica") is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine).

  • ACCESSWIRE11 months ago

    Wired News – Zomedica Inks Deal with Seraph to Develop and Market Seraph’s Novel Pathogen Detection System for Veterinarians

    LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want access to our free research report on Zomedica Pharma Corp. (NYSE: ZOM) ("Zomedica"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZOM as the Company's latest news hit the wire. On May 10, 2018, the Company announced that it has inked a deal with Seraph Biosciences, Inc. ("Seraph"), which is a human biomedical device organization, thereby securing exclusive global veterinary industry rights to develop and market Seraph's novel pathogen detection system in the form of an innovative point-of-care diagnostic instrument. Active-Investors.com is currently working on the research report for Catalent, Inc. (NYSE: CTLT), which also belongs to the Healthcare sector as the Company Zomedica Pharma.